By Elena Voss, MPH, Public Health Researcher. Medically reviewed by Dr. Lila Carter, MD, MPH, Board-Certified Obesity Medicine.
Last March, a woman named Rachel in suburban Dallas stepped on a scale at her endocrinologist's office and saw 214 pounds. She'd been on Mounjaro for sixteen weeks, titrated to the 7.5 mg dose, and had lost 19 pounds. Her first reaction? Disappointment. She'd read online that the "average" weight loss on tirzepatide was over 20% of body weight. At 214, she was down about 8%. "I told my doctor I thought it wasn't working," she said. Her doctor pulled up the actual trial data, showed her the spread within the study arms, and told her something she hadn't heard anywhere online: "You're inside the normal curve. You're responding. Don't quit."
Rachel's story is the reason this article exists. The average weight loss on Mounjaro is a real, documented number. But it's also one of the most commonly misunderstood numbers in obesity medicine right now. The mistakes people make around it are specific, predictable, and mostly fixable before they cause real harm.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the Drug Comparison (Sema vs Tirz vs Brand) hub.
The headline numbers (and what's hiding behind them)
Here's the thing about trial averages: they're summaries of thousands of individual stories, not predictions about yours.
In SURMOUNT-1, participants on the highest tirzepatide dose (15 mg) lost an average of roughly 22.5% of body weight over 72 weeks. That's a striking figure. But within that same dose arm, the spread was enormous. Some participants lost more than 25%. Others lost 10% or less. Both groups were "on Mounjaro." Both followed the trial protocol.
SURPASS-2 offered the closest thing we have to a direct head-to-head: tirzepatide versus semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Tirzepatide produced greater weight and A1c reduction. The indirect comparisons for the obesity indications tend to point the same direction, favoring tirzepatide, but trial-by-trial variance is real and individual response varies widely.
A few things worth keeping straight:
- Mechanism: semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. That dual action is likely part of why tirzepatide tends to produce larger average losses, though the science on the GIP receptor's exact contribution is still being refined.
- Liraglutide (Saxenda) is a daily injection, FDA-approved for weight management since 2014, with a longer post-marketing safety record. Semaglutide and tirzepatide are weekly.
- Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications for safety, effectiveness, or quality.
Where the real mistakes happen
About 720 people a month search "average weight loss on Mounjaro" in the U.S. What most of them are actually asking is: Will this work for me, and how much should I expect? That's a reasonable question, but the answers people cobble together from Reddit threads, TikTok, and poorly sourced articles lead to a predictable set of errors. Here are the ones that matter most.
Misreading concentration and dose
Dose instructions are written in milligrams. Syringes are calibrated in units. When compounding pharmacies change concentrations between fills (say, from 40 mg/mL to 60 mg/mL), the unit count for the same milligram dose changes. The number of people who apply an outdated unit count to a new vial is, frankly, alarming. The fix is dead simple: re-derive the unit count at every single new fill. Don't rely on memory. Do the math, or call the pharmacy and have them walk you through it.
Ignoring symptoms that aren't "normal" side effects
Mild nausea is expected on GLP-1 therapy, especially during titration. Nausea that progresses to an inability to keep fluids down is not a side effect to power through. Neither is abdominal discomfort that becomes severe and radiating, or any new symptom that doesn't fit the typical pattern. These are signals to call the prescriber or go to urgent care. Not tomorrow. Today.
Self-adjusting the dose
This one's endemic in online communities. Doubling up after a missed dose. Escalating ahead of schedule because the scale hasn't moved in two weeks. Skipping doses to "reset tolerance" (a concept with zero clinical support). Each of these is a known driver of poor outcomes. Adjustments belong in coordination with the prescriber, full stop. It is probably the single most important sentence in this article.
Treating the medication as a standalone intervention
GLP-1 therapy changes appetite and satiety signaling. That's powerful. But it does not replace protein intake, resistance training, hydration, and sleep. If anything, those inputs become more important on medication, because you're losing weight faster than your body would naturally prefer, and without adequate protein and resistance work, a meaningful chunk of that loss comes from lean mass. That's the opposite of what you want.
Comparing yourself to a trial mean
This is Rachel's mistake, and it's the most common one. A trial average is a statistical summary describing a representative participant under controlled conditions with research-grade adherence support. You are a real person with a real schedule and a refrigerator full of your kids' leftover mac and cheese. Losing weight more slowly than the trial mean does not mean the medication isn't working. It means you're inside the normal distribution that the mean summarizes. The mean is not a floor. It's a midpoint.
How to actually read a trial result
Think of it like batting averages in baseball. A .300 hitter doesn't get a hit 30% of the time in every game. Some weeks he goes 0-for-15. Other weeks he rakes. The season average is a useful summary, but it tells you almost nothing about what will happen in Tuesday's game.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →SURMOUNT-1 reported substantial differences in response within the same dose arm. That's the normal pattern across the GLP-1 trials, not an exception. Real-world cohorts add even more variance, primarily because adherence and lifestyle differ enormously outside a clinical trial.
The boring truth: across the GLP-1 class, the single strongest predictor of long-term outcome is months on therapy at or near the maintenance dose. Not which brand. Not which dose you started on. Not what supplement stack you're taking. Time on maintenance dose. Everything else matters less than that.
A note on the data cited here
The figures and protocols in this guide trace back to peer-reviewed publications and FDA prescribing information for brand-name products. Compounded formulations are not FDA-reviewed, and any practical guidance about compounded products reflects standard clinical protocol for the underlying active ingredient.
When to call your prescriber (not Google)
The default move when something feels off should be to call, not to search. Most prescriber offices and telehealth platforms have a messaging channel that produces a response within one to two business days. That's fast enough for nearly every non-emergent concern.
Course correction is easier when the problem is caught early. A dose that's escalating too fast, a side effect that's getting worse instead of plateauing, a stall that's gone on long enough to warrant a conversation: all of these are better addressed at week three than week twelve.
Related reading
- What color is semaglutide with b12?
- Why is my semaglutide red?
- Can I take Zepbound a day early?
- What happens if tirzepatide gets warm?
Frequently asked questions
Is this something I should discuss with a clinician?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered is worth raising with your prescriber. This article is general education, not a substitute for individualized clinical guidance.
Which option produces more weight loss on average?
In SURPASS-2, tirzepatide produced greater weight reduction than semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Indirect comparisons for the obesity indications also tend to favor tirzepatide, but individual response varies considerably.
Is one option safer than the other?
Both share the GLP-1 side-effect profile and class warnings. Differences in tolerability exist but are typically modest at the individual patient level. The prescriber will weigh comorbidities and contraindications when choosing the right starting agent.
Can I switch from one to the other?
Yes. Switching is a routine clinical decision. The new agent is typically started at its lowest dose and re-titrated rather than jumping to a "dose-equivalent" on day one.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
How long should I stay on Mounjaro before judging whether it's working?
Most clinicians want to see at least 12 to 16 weeks at or near the target dose before making a judgment call. Stalls during titration are common and expected. The medication needs time at therapeutic levels to show its full effect.
Why is my weight loss slower than what I see on social media?
Because social media selects for dramatic results. The person who lost 60 pounds in four months posts about it. The person who lost 18 pounds in four months (a clinically excellent result, by the way) usually doesn't. Survivorship bias is real, and it distorts expectations badly.
Continue the series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About this article
Written by Elena Voss, MPH (Public Health Researcher). Medically reviewed by Dr. Lila Carter, MD, MPH (Board-Certified Obesity Medicine). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →